Dose-escalating Phase I Trial With GEM333 in Patients With Acute Myeloid Leukemia
Status:
Active, not recruiting
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
This dose-escalating phase I trial assesses for the first time the safety, the side effects
and the harmlessness, as well as the therapeutical benefit of the new study drug GEM333 in
patients with acute myeloid leukemia (AML). This AML was relapsed after previous therapy or
was refractory to the standard therapy.